Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
82 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05980598 | TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma(BelieveIT-201) | terminated | Phase 2 | 27 | Ascendis Pharma A/SINDUSTRY | 8 | Aug 1, 2025 | clinicaltrials |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 64 | Imugene LimitedINDUSTRY | 7 | Apr 16, 2025 |
| clinicaltrials |
| NCT02423603 | PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer(PAKT) | completed | Phase 2 | 71 | Queen Mary University of LondonOTHER | 6 | Mar 10, 2025 | clinicaltrials |
| NCT04588298 | A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer(SERENA-3) | completed | Phase 2 | 135 | AstraZenecaINDUSTRY | 3 | Jan 24, 2025 | clinicaltrials |
| NCT02708680 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | completed | Phase 1 / Phase 2 | 89 | Syndax PharmaceuticalsINDUSTRY | 2 | Dec 4, 2024 | clinicaltrials |
| NCT02216786 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer(MANTA) | completed | Phase 2 | 333 | Queen Mary University of LondonOTHER | 9 | Dec 2, 2024 | clinicaltrials |
| NCT02124668 | A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 30 | Astellas Pharma Europe B.V.INDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03427814 | Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer | completed | Phase 2 | 136 | BeiGeneINDUSTRY | 16 | Oct 26, 2024 | clinicaltrials |
| NCT04204057 | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 21 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | Aug 13, 2024 | clinicaltrials |
| NCT05021900 | Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 40 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03711604 | Compassionate Use Study of Tenalisib (RP6530) | completed | Phase 1 / Phase 2 | 17 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | May 8, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT04622007 | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)(KICKSTART) | unknown | Phase 2 | 68 | Effector TherapeuticsINDUSTRY | 3 | Apr 30, 2024 | clinicaltrials |
| NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma(DYNAMO) | completed | Phase 2 | 129 | SecuraBioINDUSTRY | 12 | Sep 7, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT01724866 | Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer | completed | Phase 2 | 148 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Apr 15, 2022 | clinicaltrials |
| NCT02941523 | Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours | completed | Phase 1 / Phase 2 | 19 | Noxopharm LimitedINDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT02207530 | Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 112 | AstraZenecaINDUSTRY | 14 | Sep 29, 2020 | clinicaltrials |
| NCT02319044 | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 267 | AstraZenecaINDUSTRY | 15 | Sep 29, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT00866970 | Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia | completed | Phase 2 | 124 | CSL BehringINDUSTRY | 9 | Jul 9, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3(HPV-003) | completed | Phase 2 | 167 | Inovio PharmaceuticalsINDUSTRY | 9 | Sep 7, 2018 | clinicaltrials |
| NCT01619423 | A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer(PLIANT) | completed | Phase 1 / Phase 2 | 186 | Egetis TherapeuticsINDUSTRY | 8 | Jul 6, 2018 | clinicaltrials |
| NCT00669591 | A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer | completed | Phase 2 | 46 | Peregrine PharmaceuticalsINDUSTRY | 1 | Apr 21, 2017 | clinicaltrials |
| NCT01138163 | Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer | completed | Phase 2 | 121 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | completed | Phase 2 | 86 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT00431561 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | completed | Phase 2 | 141 | Isarna Therapeutics GmbHINDUSTRY | 6 | Dec 3, 2013 | clinicaltrials |
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | completed | Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 19, 2012 | clinicaltrials |
| NCT01066494 | A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 20 | Antisoma ResearchINDUSTRY | 2 | Jan 17, 2011 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials